Single Antiplatelet Therapy Transition Tool for High Bleeding Risk

Single Antiplatelet Therapy Transition for High Bleeding Risk: Explanation and Clinical Context
Transition from dual antiplatelet therapy to single antiplatelet therapy is supported in the management of high bleeding risk patients after percutaneous coronary intervention according to the AHA ACS Guideline 2025. For patients with elevated bleeding tendency a shorter DAPT duration is reasonable and may safely reduce hemorrhagic complications without significantly increasing ischemic events especially when adequate stent deployment and stable clinical presentation are confirmed. A single antiplatelet regimen can be introduced commonly after three months when no recurrent ischemia or stent thrombosis is observed. P2Y12 monotherapy has shown favorable risk balance in several randomized studies as alternative to prolonged DAPT. Transition decisions should consider dual goals of ischemic protection and bleeding minimization while incorporating clinical judgment patient stability age kidney function and prior bleeding history.

Reference:
American Heart Association Guideline for Acute Coronary Syndromes Management 2025. Section on antiplatelet strategy for high bleeding risk including DAPT shortening and SAPT transition after PCI period recommendation. Relevant tables and narrative guidance ACS pharmacotherapy chapter.

No discussions yet. Be the first to comment.